



Summary of Studies Supporting USDA Product Licensure

| | |
|---|-------------------------------------|
| Establishment Name | Addison Biological Laboratory, Inc. |
| USDA Vet Biologics Establishment Number | 355 |
| Product Code | 2A77.00 |
| True Name | Moraxella Bovoculi Bacterin |
| Tradename(s)/Distributor (if different from manufacturer) | |
| Date of Compilation Summary | January 12, 2017 |

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

| Study Type | Safety | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|--|---------------------------------|---|--|--|--------|--|-------------------------|---------------------------------|---|---|--|---|----|----|---|---------------------------------------|---|----------|---|---|----------------------------|---|----------|---|--|--|--|--|--|--------|--|-------------------------|---------------------------------|---|---|---------------------------|---|----|----|
| Pertaining to | Moraxella bovoculi Bacterin | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Study Purpose | Demonstrate safety of Bacterin under typical field use conditions | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Product Administration | 2 Doses administered subcutaneously 21 days apart. (Day 0 and Day 21) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Study Animals | 611 head of cattle were vaccinated with at least 200 head in each of three distinct geographic regions. At least 1/3 of the animals vaccinated in each of the three regions were the minimum age recommended for product administration. Region 1 included 200 cattle. Region 2 included 201 cattle. Region 3 included 210 cattle. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Challenge Description | NA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Interval observed after challenge | Cattle were observed immediately after vaccination and once daily for 42 days after the first vaccination. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Results | <table><tr><th colspan="5">Injection Site Reactions Following 1st Dose of Vaccine</th></tr><tr><th>Region</th><th>Time following first vaccination when first observed</th><th># of reactions recorded</th><th>Range of size of Reactions (mm)</th><th>Resolved prior to 2nd dose of vaccine</th></tr><tr><td>1</td><td>1 and 2 weeks following 1st dose</td><td>0</td><td>NA</td><td>NA</td></tr><tr><td>2</td><td>1 week following 1st dose</td><td>6</td><td>25-30 mm</td><td>6</td></tr><tr><td>2</td><td>2 weeks following 1st dose</td><td>2</td><td>20-24 mm</td><td>2</td></tr></table> <table><tr><th colspan="5">Injection Site Reactions Following 2nd Dose of Vaccine</th></tr><tr><th>Region</th><th>Time following first vaccination when first observed</th><th># of reactions recorded</th><th>Range of size of Reactions (mm)</th><th>% Resolved prior to end of study or 2 weeks following first observation</th></tr><tr><td>1</td><td>1 week following 2nd dose</td><td>0</td><td>NA</td><td>NA</td></tr></table> | Injection Site Reactions Following 1 st Dose of Vaccine | | | | | Region | Time following first vaccination when first observed | # of reactions recorded | Range of size of Reactions (mm) | Resolved prior to 2 nd dose of vaccine | 1 | 1 and 2 weeks following 1 st dose | 0 | NA | NA | 2 | 1 week following 1 st dose | 6 | 25-30 mm | 6 | 2 | 2 weeks following 1st dose | 2 | 20-24 mm | 2 | Injection Site Reactions Following 2nd Dose of Vaccine | | | | | Region | Time following first vaccination when first observed | # of reactions recorded | Range of size of Reactions (mm) | % Resolved prior to end of study or 2 weeks following first observation | 1 | 1 week following 2nd dose | 0 | NA | NA |
| Injection Site Reactions Following 1 st Dose of Vaccine | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Region | Time following first vaccination when first observed | # of reactions recorded | Range of size of Reactions (mm) | Resolved prior to 2 nd dose of vaccine | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | 1 and 2 weeks following 1 st dose | 0 | NA | NA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | 1 week following 1 st dose | 6 | 25-30 mm | 6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | 2 weeks following 1st dose | 2 | 20-24 mm | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Injection Site Reactions Following 2nd Dose of Vaccine | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Region | Time following first vaccination when first observed | # of reactions recorded | Range of size of Reactions (mm) | % Resolved prior to end of study or 2 weeks following first observation | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | 1 week following 2nd dose | 0 | NA | NA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | | | |
|---------------------------|--|---|------------------------------------|--|--|
| | 2 | 1 week following 2nd dose | 30 | 25-75 mm | 13 |
| | 3 | 1 week following 2 nd dose | 5 | 40-51 mm | 0 |
| | | | | | |
| | Injection Site Reactions First Observed on Day 42 (Final Day of Study) | | | | |
| | Region | Time following first vaccination when first observed | # of reactions recorded | Range of size of Reactions (mm) | % Resolved |
| | 1 | 3 weeks following 2nd dose | 0 | NA | NA |
| | 2 | 3 weeks following 2nd dose | 17 | 7-39 mm | Unknown since calves were not followed past Day 42 |
| | 3 | 3 weeks following 2nd dose | 2 | 9-12 mm | |
| | Adverse Events affirmed by licensee to have possible cause other than vaccine | | | | |
| | Event | Region | Comments | # of Animals | Day of Study |
| | Respiratory Tract Disorder | 1 & 3 | Abnormal beathing; nasal discharge | 3 | Day 14 Region 1; Day 29 Region 3 |
| Eye Disorder | 2 | Trauma induced corneal ulcer | 2 | Day 12 | |
| None | 1, 2, 3 | | 0 | | |
| NA is not applicable | | | | | |
| USDA Approval Date | July 20, 2016 | | | | |